Rapport Therapeutics reports Q1 EPS (68c) vs. ($11.07) last year

“2025 represents a transformational year for Rapport as we prepare to deliver our initial proof-of-concept data for RAP-219 from the Phase 2a trial in patients with refractory focal epilepsy and progress our pipeline-in-a-product strategy with the initiation of our bipolar mania trial. Rapport’s first quarter demonstrated our continued ability to execute our clinical development efforts, and we remain confident that we are on track to deliver on our development milestones. Enrollment in the Phase 2a trial in patients with refractory focal epilepsy is progressing as planned, and we are observing a growing level of excitement in the epilepsy community for the data, given the innovative trial design and its potential to evolve epilepsy drug development,” said Abraham N. Ceesay, CEO of Rapport. “The recent PET and MAD-2 trial results further validate the neuroanatomical specificity of TARPgamma8 and favorable tolerability profile of RAP-219. When combined with the strong preclinical anti-seizure effects seen, these findings reinforce our confidence in RAP-219’s differentiated precision profile.”